Last reviewed · How we verify
Euvax B®: Hepatitis B vaccine
Euvax B stimulates the immune system to produce antibodies against hepatitis B virus surface antigen, providing protection against hepatitis B infection.
Euvax B stimulates the immune system to produce antibodies against hepatitis B virus surface antigen, providing protection against hepatitis B infection. Used for Prevention of hepatitis B infection in infants, children, and adults.
At a glance
| Generic name | Euvax B®: Hepatitis B vaccine |
|---|---|
| Also known as | Euvax B® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This is an inactivated hepatitis B vaccine containing recombinant hepatitis B surface antigen (HBsAg) produced in yeast cells. Upon administration, it triggers both humoral and cellular immune responses, leading to the production of anti-HBs antibodies that neutralize the virus and provide long-term immunity against hepatitis B infection.
Approved indications
- Prevention of hepatitis B infection in infants, children, and adults
Common side effects
- Injection site pain or soreness
- Fever
- Fatigue
- Headache
Key clinical trials
- Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. (PHASE3)
- A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults (PHASE1)
- DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |